

REMARKS

The Initial Patent Examination Center states that the application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences as set forth in 37 CFR 1.821(a)(1) and (a)(2).


Applicant notes that 37 CFR 1.821(b) states that: "(b) Patent applications which contain disclosures of nucleotide and/or amino acid sequences, in accordance with the definition in paragraph (a) of this section, shall, with regard to the manner in which the nucleotide and/or amino acid sequences are presented and described, conform exclusively to the requirements of Sections 1.821 through 1.825."

Applicant respectfully submits that the application does not disclose or make claim to any specific or novel nucleotide sequences. The application describes generic techniques to determine DNA sequence information, such as DNA molecule length or nucleotide composition. These general references are made in order to enable the practice of a novel method that is broadly applicable to DNA. No claim is made to any particular nucleotide sequence, and any such specific sequence mentioned would be used solely for illustrative purposes and would not represent a novel sequence disclosure. Therefore, since the application does not contain any material "disclosure of nucleotide sequences", applicant

respectfully submits that CFR 1.821 through 1.825 are not applicable to any disclosed sequences in the application.

CERTIFICATE OF MAILING

I hereby certify that the correspondence is
being deposited with the United States Postal
Service as first class mail in an envelope
addressed to Commissioner of Patents and
Trademarks, Washington, DC 20231.




Ansel M. Schwartz
Registration No. 30,587


Date

Respectfully submitted,

MARK W. PERLIN

By 

Ansel M. Schwartz, Esquire

Reg. No. 30,587

One Sterling Plaza

201 N. Craig Street

Suite 304

Pittsburgh, PA 15213

(412) 621-9222

Attorney for Applicant